TCR-T细胞治疗实体肿瘤的研究进展  

Research Progress of TCR-T Cells for the Treatment of Solid Tumors

作　　者：张亚静 周鹏辉 ZHANG Yajing;ZHOU Penghui(State Key Laboratory of Oncology in South China,Guangdong Provincial Clinical Research Center for Cancer,Sun Yat-sen University Cancer Center,Guangzhou 510060,China)

机构地区：[1]华南恶性肿瘤防治全国重点实验室,广东省恶性肿瘤临床医学研究中心,中山大学肿瘤防治中心,广州510060

出　　处：《中国细胞生物学学报》2025年第3期730-741,共12页Chinese Journal of Cell Biology

基　　金：国家自然科学基金(批准号:82130086、82192892、82402143)资助的课题。

摘　　要：以基因工程化T细胞为基础的过继性细胞治疗改变了肿瘤免疫治疗的格局,成为了最有希望攻克癌症的方向。嵌合抗原受体T细胞(CAR-T)疗法在血液肿瘤的治疗中显示出显著的疗效,但在实体瘤治疗中至今未有令人满意的结果。T细胞受体工程T细胞(TCR-T)疗法在实体肿瘤的治疗中显示出良好的应用前景。该综述总结了靶向不同肿瘤抗原的TCR-T细胞疗法取得的临床结果,讨论了TCR-T细胞疗法目前的局限性和面临的挑战。最后,该文展望了TCR-T疗法的优化策略和未来发展方向。Genetically engineered T-cell therapy has become the most promising approach for the treatment of solid tumors.Although CAR-T(chimeric antigen receptor T-cell)therapy has shown remarkable efficacy in the treatment of hematological malignancies,the efficacy of treating solid tumors remains at low levels.TCR-T(T cell receptor-engineered T cell)therapies have shown encouraging results in the treatment of solid tumors.This review describes the clinical results achieved by TCR-T cell therapies targeting different tumor antigens,and summarizes current limitations and challenges of TCR-T cell therapies.Finally,this study discusses the improving strategies and future directions of TCR-T therapies.

关 键 词：实体肿瘤 免疫治疗 肿瘤抗原 T细胞受体工程T细胞 

分 类 号：R73[医药卫生—肿瘤]